RxDoctor Payments Data

Stephen Mester, MD

Cardiovascular Disease · Brandon, FLNPI 1457313470

Payments from drug & device makers

$288,848in general payments, 2019–2025

Across 156 payments — averaging $1851.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$150K
  • Abbott$115K
  • Boston Scientific$14K
  • Astellas Pharma US Inc$9K
  • Abiomed$115
  • Cardiva Medical, Inc.$93
  • plus $223 from 6 others

What the payments were for

  • Consulting fees$10,12551%
  • Speaking & faculty fees$8,90045%
  • Food & beverage$7574%
  • Education$910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$288,848 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$407,800
Medicare patients
1,002
Services billed
3,093

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban334$424,281
EntrestoSacubitril/Valsartan112$150,690
XareltoRivaroxaban58$59,537
FarxigaDapagliflozin Propanediol42$53,419
BrilintaTicagrelor35$43,476
JardianceEmpagliflozin18$32,295
Repatha SureclickEvolocumab24$23,496
Repatha SyringeEvolocumab11$10,722
Dabigatran EtexilateDabigatran Etexilate Mesylate20$7,955
Metoprolol Succinate417$6,320
ClopidogrelClopidogrel Bisulfate271$3,684
Ranolazine ErRanolazine24$2,446
Atorvastatin Calcium191$1,655
Amiodarone Hcl53$1,296
Rosuvastatin Calcium130$1,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$45$59,53758 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →